CDI Bioscience
1
40M
1
0.07
1
- Areas of investment
Summary
In 2007 was created CDI Bioscience, which is appeared as Corporate Investor. The main department of described Corporate Investor is located in the Madison. The company was established in North America in United States.
The standard case for the fund is to invest in rounds with 9 partakers. The meaningful sponsors for the fund in investment in the same round are Novo Holdings, New Medical Technologies, Manulife Financial. In the next rounds fund is usually obtained by Vulcan Capital, Novo Holdings, HealthCap.
The common things for fund are deals in the range of 10 - 50 millions dollars. The increased amount of exits for fund were in 2013. The top activity for fund was in 2001. The fund is constantly included in less than 2 deals per year.
Among the most successful fund investment fields, there are Biotechnology, Therapeutics. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Besides, a startup requires to be at the age of 2-3 years to receive the investment from the fund. Among the various public portfolio startups of the fund, we may underline PTC Therapeutics
This organization was formed by Victor Levenson, Vitaliy Gavrilyuk.
Investments analytics
Analytics
- Total investments
- 1
- Lead investments
- 0
- Exits
- 1
- Rounds per year
- 0.07
- Investments by industry
- Biotechnology (1)
- Therapeutics (1)
- Health Care (1)
- Investments by region
-
- United States (1)
- Peak activity year
- 2001
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 23
- Group Appearance index
- 1.00
- Strategy success index
- 1.00
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.